Preclinical Humanised Mouse Models for CD47/Sirpa Targeted Cancer Immunotherapies In Vivo
Time: 11:30 am
day: Discovery & Pre-Clinical Development – Day 2 am
- Human macrophages enhance tumor cell growth in vivo
- – Anti-human SIRPα antibody inhibit B-cell lymphoma growth in cooperation with Rituximab in vivo.
- – Anti-human SIRPα antibody alter the function of tumor infiltrating macrophages